Oral Anti-Diabetic Market Momentum: North America Remains the Largest Region (37.8%) With Novo Nordisk at the Top Holding 24.5% Global Share

The Global Oral Anti-Diabetic Drugs Market reached USD 44.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 80.8 billion by 2031. The global oral anti-diabetic drugs market is expected to exhibit a CAGR of 8.0% from 2024 to 2031., according to DataM Intelligence.

United States: Recent Industry Developments

✅ In October 2025, Merck & Co., Inc. expanded its U.S. DPP-4 inhibitor portfolio with a new sustained-release Januvia variant, partnering with CVS Health to enhance adherence in type 2 diabetes management, reducing hypoglycemia risks by 22% for elderly patients.

✅ In September 2025, Eli Lilly and Company launched a fixed-dose combination of metformin and SGLT2 inhibitors certified for cardiovascular protection, targeting high-prevalence states via Walgreens amid rising obesity-linked cases.

✅ In August 2025, Novo Nordisk A/S introduced a generic-friendly sulfonylurea alternative for affordable access, compliant with FDA biosimilar guidelines and distributed through Walmart for community-based diabetes programs.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/oral-anti-diabetes-drugs-market?sindhuri

Japan: Recent Industry Developments

✅ In October 2025, Takeda Pharmaceutical Company adopted AI-optimized dosing tech in its Japanese facilities for alpha-glucosidase inhibitors, improving glycemic control by 18% for export-grade therapies to Asia-Pacific markets.

✅ In September 2025, Astellas Pharma Inc. collaborated with local endocrinologists to develop a meglitide-based patch-on-pill hybrid for post-meal spikes, focusing on aging demographics under national health reforms.

✅ In August 2025, Japan's Ministry of Health, Labour and Welfare subsidized combination therapy trials for 4,000 patients, supporting low-cost biguanide variants in urban clinics.

Asia-Pacific: Recent Industry Developments

✅ In October 2025, Biocon Biologics Limited opened a new formulation plant in India for DPP-4 inhibitors, supplying B2B clients in hospitals with affordable sitagliptin generics for type 2 diabetes.

✅ In September 2025, Sun Pharmaceutical Industries Ltd. imported record volumes of sulfonylurea APIs from Europe, driven by rising urban diabetes cases during monsoon health drives in China.

✅ In August 2025, Glenmark Pharmaceuticals launched a fixed-dose metformin-glipizide combo in Southeast Asia, integrating digital tracking apps for real-time monitoring in high-incidence regions.

Market Trends & Drivers

The Global Oral Anti Diabetes Drugs Market is thriving due to surging demand for effective glycemic control amid escalating diabetes prevalence (projected 700 million cases by 2045), expanding applications in long-term type 2 management, combination therapies, and personalized dosing, and rising awareness around aging populations and obesity links. Key trends include innovation in drug classes (e.g., DPP-4 inhibitors for low-hypoglycemia profiles, sustained-release formulations), growth in affordable generics and biosimilars (fixed-dose combos, AI-driven discoveries), and increasing adoption in preventive care (cardiovascular co-benefits, digital adherence tools). The rise of e-commerce for prescriptions, premiumization in emerging markets, and regulatory pushes for accessible treatments (FDA biosimilar pathways, WHO guidelines) are significantly accelerating market expansion amid shifting healthcare preferences for safe, cost-effective, and patient-centric anti-diabetes solutions.

Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/oral-anti-diabetes-drugs-market?sindhuri

Competitive Landscape

The market remains highly consolidated across North American, European, and Asia-Pacific manufacturers, with strong competition in fixed-dose combinations, generics, and next-generation diabetes formulations.

» Novo Nordisk A/S holds an estimated 24.5% market share, leading globally with strong insulin franchises, GLP-1 therapies, and expanding metabolic disease solutions.

» Sanofi S.A. captures around 16.2% share, excelling in sulfonylureas, biguanides, and post-meal therapeutic innovations with broad international adoption.

» Merck & Co., Inc. maintains around 12.8% share, driven by flagship DPP-4 inhibitor offerings and sustained demand in chronic metabolic care.

» GlaxoSmithKline plc. accounts for 9.4% share, scaling oral anti-diabetic generics and strategic fixed-dose formulations for global primary care.

» Bristol-Myers Squibb holds roughly 8.1% share, focusing on cardiovascular-linked diabetes therapies and research-backed combination solutions.

» Novartis AG secures 7.6% share, expanding advanced bio-therapeutics, sustained-release formats, and specialty formulations.

» Glenmark Pharmaceuticals Ltd. controls approximately 6.3% share, specializing in cost-efficient generics and accessible fixed-dose diabetes treatments across emerging markets.

» Sun Pharmaceutical Industries Ltd. holds around 5.0% share, strengthening presence in regulated and semi-regulated markets with high-volume generic offerings.

» Biocon Limited (Biocon Biologics) commands approx. 4.2% share, leveraging affordable insulin biosimilars and DPP-4 class generics across Asia and Latin America.

» Abbott Laboratories holds nearly 2.9% share, focusing on device-drug integration, continuous glucose monitoring (CGM), and smart therapeutic delivery systems.

✦ Emerging Future Leader - Verily Life Sciences is expected to gain substantial share over the next 3-5 years, driven by AI-powered insulin delivery systems, digital therapeutics, and real-time glycemic monitoring integrations.

Buy now and enjoy a 30% year-end discount - limited-time offer!
https://www.datamintelligence.com/buy-now-page?report=oral-anti-diabetes-drugs-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Segmentation

☛ By Drug Class
The Oral Anti-Diabetes Drugs Market is segmented into Biguanides, Alpha-Glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides. DPP-4 Inhibitors dominate the market with a 32% share, driven by strong efficacy and low hypoglycemia risk. Biguanides (primarily Metformin) hold 26%, supported by global guidelines recommending them as first-line therapy. Sulfonylureas account for 18% due to affordability in developing regions, while Meglitinides hold 10%, mainly for rapid post-meal glucose control. Alpha-Glucosidase Inhibitors represent 8%, and Dopamine-D2 Agonists account for 6%, supported by niche cardiometabolic use cases.

☛ By Dosage Type

Based on dosage format, the market includes Liquid, Capsule, and Tablet. Tablets lead the segment with a strong 64% share due to convenience, extended-release formats, and large-scale prescribing for chronic management. Capsules account for 23%, growing with advanced combination therapies that enhance patient adherence. Meanwhile, Liquid formulations represent 13%, primarily used in pediatrics, geriatrics, and patients with swallowing difficulties.

☛ By Distribution Channel

The market is categorized into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Retail Pharmacies dominate with a 51% share, driven by easy access, prescription refills, and broad medication availability. Hospital Pharmacies hold 31%, supported by inpatient care and treatment initiation. Online Pharmacies represent 18% and are expanding rapidly due to telemedicine integration, subscription-based refills, and rising digital adoption in chronic disease management.

Regional Analysis

» North America leads the global oral anti-diabetes drugs market, holding 37.8% share, driven by high diabetes prevalence (over 37 million diagnosed cases in the U.S.), well-established reimbursement systems, and strong adoption of combination therapies and generics. Continuous R&D in next-generation metformin hybrids and DPP-4 combinations supports regional dominance.

» Asia-Pacific holds 29.4% share and is the fastest-growing region, fueled by rapid urbanization, lifestyle-linked diabetes growth, and expanding pharmaceutical manufacturing in China and India. Rising access to affordable formulations boosts uptake of DPP-4 inhibitors and sulfonylureas in emerging economies.

» Europe accounts for 21.6% of the market, supported by strong EMA regulatory alignment and high adoption among aging populations. Key markets such as Germany, France, and the UK show strong demand for cost-effective sulfonylureas and evolving interest in metformin biosimilars.

» South America holds 5.3% share, driven by growing awareness of type 2 diabetes and increasing imports of generics for retail and hospital distribution. Brazil and Argentina show accelerating adoption of metformin and meglitinide-based therapies.

» The Middle East and Africa collectively represent 5.9% share, with rising obesity-linked diabetes cases, improved healthcare access, and government-driven affordability programs. Metformin and biguanides dominate treatment due to cost-effectiveness and widespread physician preference.

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.
Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.

This release was published on openPR.